<p>On this episode of <strong>Alloutcoach</strong>, host <strong>Tim Mikhelashvili, CEO, Amedea Pharma </strong>convenes a panel you rarely hear in one room: a policy-minded biohacker and investor (<strong>John Hemming, CEO of Cirrostratus, Biohacking Team Leader</strong>), a strategy and operations leader who reshapes patient journeys (<strong>Bart Zoni, Senior Vice President, Marketing, Woven Health Collective</strong>), and an early-stage investor focused on medical technologies (<strong>Chris Piedmonte, Managing Director, Neoterra Capital</strong>) as well as a senior pharma thought leader in Medical Affairs and Health Economics, <strong>Janelle Hardisty</strong>. Their catalyst? Fresh takeaways from the 2025 Financial Times US Pharma summit — and an honest look at what’s truly accelerating innovation, what’s stalling it, and where capital and talent should go next.</p><p>00:00:00 Cold Open - Episode Highlights: AI accuracy and access<br>00:03:43 Host Intro and Why This Episode<br>00:04:41 Guest Intros<br>00:08:06 State of Innovation - Tailwinds and Headwinds<br>00:12:41 What’s Really Accelerating Innovation?<br>00:19:27 Drug Discovery - Reducing the 90% Failure Rate<br>00:22:01 Clinical Trials - Modernize or Stall<br>00:25:11 Access, PBMs, and Direct-to-Patient<br>00:27:03 Longevity and Prevention - Can We Measure It?<br>00:36:52 Data Culture Maturity and Pilot Fatigue<br>00:45:52 Training the Future Workforce<br>00:51:09 Investing - Where Should Capital Flow?<br>00:57:08 Regulatory Reality and Time-to-Access<br>00:59:27 Closing and Invite to Medical Innovation Olympics</p>

Alloutcoach

ALLOUTCOACH

STATE OF INVESTMENT AND INNOVATION IN HEALTHCARE: 2025 Financial Times US Pharma Summit

OCT 5, 202560 MIN
Alloutcoach

STATE OF INVESTMENT AND INNOVATION IN HEALTHCARE: 2025 Financial Times US Pharma Summit

OCT 5, 202560 MIN

Description

<p>On this episode of <strong>Alloutcoach</strong>, host <strong>Tim Mikhelashvili, CEO, Amedea Pharma </strong>convenes a panel you rarely hear in one room: a policy-minded biohacker and investor (<strong>John Hemming, CEO of Cirrostratus, Biohacking Team Leader</strong>), a strategy and operations leader who reshapes patient journeys (<strong>Bart Zoni, Senior Vice President, Marketing, Woven Health Collective</strong>), and an early-stage investor focused on medical technologies (<strong>Chris Piedmonte, Managing Director, Neoterra Capital</strong>) as well as a senior pharma thought leader in Medical Affairs and Health Economics, <strong>Janelle Hardisty</strong>. Their catalyst? Fresh takeaways from the 2025 Financial Times US Pharma summit — and an honest look at what’s truly accelerating innovation, what’s stalling it, and where capital and talent should go next.</p><p>00:00:00 Cold Open - Episode Highlights: AI accuracy and access<br>00:03:43 Host Intro and Why This Episode<br>00:04:41 Guest Intros<br>00:08:06 State of Innovation - Tailwinds and Headwinds<br>00:12:41 What’s Really Accelerating Innovation?<br>00:19:27 Drug Discovery - Reducing the 90% Failure Rate<br>00:22:01 Clinical Trials - Modernize or Stall<br>00:25:11 Access, PBMs, and Direct-to-Patient<br>00:27:03 Longevity and Prevention - Can We Measure It?<br>00:36:52 Data Culture Maturity and Pilot Fatigue<br>00:45:52 Training the Future Workforce<br>00:51:09 Investing - Where Should Capital Flow?<br>00:57:08 Regulatory Reality and Time-to-Access<br>00:59:27 Closing and Invite to Medical Innovation Olympics</p>